We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

33 hedge funds and large institutions have $32.8M invested in Astria Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

944% more call options, than puts

Call options by funds: $3.23M | Put options by funds: $310K

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

6% less funds holding

Funds holding: 35 → 33 (-2)

9.38% less ownership

Funds ownership: 56.22% → 46.84% (-9.4%)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

49% less capital invested

Capital invested by funds: $63.8M → $32.8M (-$30.9M)

Holders
33
Holders Change
-2
Holders Change %
-5.71%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
7
Closed
7
Calls
$3.23M
Puts
$310K
Net Calls
+$2.92M
Net Calls Change
+$3.02M

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$329K
2
BCM
Bridgeway Capital Management
Texas
+$296K
3
Wolverine Trading
Wolverine Trading
Illinois
+$84.4K
4
BlackRock
BlackRock
New York
+$78.6K
5
Millennium Management
Millennium Management
New York
+$67.5K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$4.46M
2
CC
Commodore Capital
New York
-$2.12M
3
SCM
Soleus Capital Management
Connecticut
-$994K
4
Citadel Advisors
Citadel Advisors
Florida
-$580K
5
Renaissance Technologies
Renaissance Technologies
New York
-$493K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$6.91M -$4.46M -678,455 -35%
RCM
2
RA Capital Management
Massachusetts
$6.8M – – –
FFM
3
Fairmount Funds Management
Pennsylvania
$4.91M – – –
CAM
4
Cormorant Asset Management
Massachusetts
$2.98M – – –
VA
5
VR Adviser
New York
$2.9M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.87M -$140K -21,330 -4%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$1.48M +$329K +50,000 +22%
Citadel Advisors
8
Citadel Advisors
Florida
$1.2M -$580K -88,192 -28%
IC
9
Ikarian Capital
Texas
$473K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$350K +$29.5K +4,484 +7%
BlackRock
11
BlackRock
New York
$287K +$78.6K +11,957 +29%
BCM
12
Bridgeway Capital Management
Texas
$243K +$296K +45,000 New
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$206K -$51.7K -7,863 -17%
Renaissance Technologies
14
Renaissance Technologies
New York
$185K -$493K -74,992 -69%
AG
15
Artal Group
Luxembourg
$180K – – –
AI
16
ArchPoint Investors
Florida
$139K -$16.4K -2,500 -9%
SB
17
Samsara BioCapital
California
$135K – – –
Northern Trust
18
Northern Trust
Illinois
$119K +$18.2K +2,760 +14%
OC
19
Oppenheimer & Co
New York
$118K +$62.9K +9,567 +78%
OQS
20
Occudo Quantitative Strategies
Florida
$83K – – –
OWP
21
Old Well Partners
North Carolina
$65K – – –
Wolverine Trading
22
Wolverine Trading
Illinois
$65K +$84.4K +12,836 New
Millennium Management
23
Millennium Management
New York
$55K +$67.5K +10,259 New
Bank of America
24
Bank of America
North Carolina
$21K +$17.3K +2,630 +206%
UBS Group
25
UBS Group
Switzerland
$18K +$1.57K +239 +8%
1
2

ATXS Hedge Fund Activity: Q4 2021 in Review

33 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2021, worth a combined $32.8M — down 49% from $63.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ATXS and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was Alyeska Investment Group, adding an estimated $329K. The largest seller was Perceptive Advisors, cutting an estimated $4.46M.

  • 33 institutional investors held Astria Therapeutics (ATXS) as of Q4 2021, down from 35 in Q3 2021.
  • Funds reported $32.8M of Astria Therapeutics stock for Q4 2021, down 49% quarter-over-quarter.
  • 5 funds opened new Astria Therapeutics positions in Q4 2021 and 7 closed out, a net change of -2 holders.
  • The largest Astria Therapeutics buyer in Q4 2021 was Alyeska Investment Group, an estimated $329K added.
  • The largest Astria Therapeutics seller in Q4 2021 was Perceptive Advisors, an estimated $4.46M sold.

Based on aggregated 13F filings for Q4 2021.